Adenoid Cystic Carcinoma
Pipeline by Development Stage
Drug Modality Breakdown
Adenoid Cystic Carcinoma is a $4.3B market in consolidation, heavily dependent on off-label use of established oncology assets with limited disease-specific innovation.
Key Trends
- Market dominated by single off-label immunomodulatory agent (REVLIMID, 91% share) facing patent cliff in 2028
- Early-stage pipeline shows modest activity (26 trials, mostly Phase 1/2) with no clear breakthrough mechanisms emerging
- Significant unmet need: only 3 marketed products, all with secondary indication status, creating white space for ACC-focused therapies
Career Verdict
Specializing in ACC offers moderate opportunity: the market is stable but faces near-term revenue disruption, making it suitable for professionals interested in niche oncology with potential for transformative innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | REVLIMID (lenalidomide) | Bristol Myers Squibb | $3.9B | 91% | LOE_APPROACHING | Declining | 1.8yr |
| 2 | INLYTA (axitinib) | Pfizer | $467M | 11% | PEAK | Stable | 11.2yr |
| 3 | PADCEV (enfortumab vedotin) | Astellas | $4M | 0% | PEAK | Stable |
Drug Class Breakdown
facing 2028 patent expiry
modest niche positioning
emerging, minimal traction
Career Outlook
DecliningACC is a contracting market facing a critical inflection point in 2028 when REVLIMID exclusivity ends. The field is characterized by limited disease-specific expertise and off-label reliance, creating both risk for established commercial roles and genuine opportunity for innovative researchers and precision oncology specialists. Professionals entering now should expect portfolio disruption but may position themselves to lead next-generation ACC drug development if they invest in early-stage pipeline understanding.
Breaking In
Entry-level professionals should target roles in Clinical Operations or R&D at BMS/Pfizer with explicit ACC focus; avoid early-career pure commercial roles given near-term revenue contraction.
For Experienced Professionals
Experienced professionals should consider transitioning into pipeline development, biomarker strategy, or regulatory roles to position for the post-2028 reshuffling and potential breakthrough ACC therapies in Phase 1/2.
In-Demand Skills
Best For
Hiring Landscape
Hiring is concentrated at BMS (694 roles) and Pfizer (528 roles), with Manufacturing dominating (387 roles) due to supply chain demands for REVLIMID. Medical Affairs and Commercial roles command premium salaries ($412K and $221K respectively), reflecting the complexity of promoting off-label use in a rare indication. Post-2028 patent loss will likely compress hiring across both companies.
By Department
Medical Affairs and Clinical Operations offer the highest compensation, but job security is tied to pre-2028 REVLIMID revenue; manufacturing roles face the greatest post-LOE contraction risk.
Competitive Landscape
13 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (15)
Total enrollment: 979 patients across 15 trials
Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617
Axitinib Pharmacokinetics in Chinese Healthy Volunteers
Related Jobs in Oncology
Senior IT Infrastructure Engineer
Clinical Data Associate
Vice President and Head of Business Development
Associate Scientist (BS/MS) contractor – Lentiviral Vector Research & Early Process Development (100% Bench)
Medical Director, Early-Stage Clinical Development
Business Director Oncology BENELUX
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.